Response and Toxicity to the Second Course of 3 Cycles of 177Lu-PSMA Therapy Every 4 Weeks in Patients with Metastatic Castration-Resistant Prostate Cancer.
Sazan RasulTim WollenweberLucia ZisserElisabeth Kretschmer-ChottBernhard GrubmüllerGero KramerShahrokh F ShariatHarald EidherrMarkus MitterhauserChrysoula VrakaWerner LangstegerMarcus HackerAlexander R HaugPublished in: Cancers (2021)
A further intensive PSMA-RLT course is well tolerated in mCRPC patients and associated with promising response rates and OS.